Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patient...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Aydinok, Yesim, Kattamis, Antonis, Cappellini, M. Domenica, El-Beshlawy, Amal, Origa, Raffaella, Elalfy, Mohsen, Kilinç, Yurdanur, Perrotta, Silverio, Karakas, Zeynep, Viprakasit, Vip, Habr, Dany, Constantinovici, Niculae, Shen, Junwu, Porter, John B.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2015
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490296/
https://ncbi.nlm.nih.gov/pubmed/25934475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-586677
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires